Polyneuron Pharmaceuticals

Polyneuron is proud to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN‑1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of safe and effective therapies for the treatment of rare diseases. The FDA may provide grant funding toward clinical trial costs, tax credits, FDA user-fee benefits, and seven years of market exclusivity following marketing approval.